GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 166 filers reported holding GENMARK DIAGNOSTICS INC in Q3 2020. The put-call ratio across all filers is 3.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,050,000 | -61.4% | 43,953 | -76.4% | 0.08% | -59.2% |
| Q4 2020 | $2,721,000 | +28.0% | 186,371 | +24.5% | 0.18% | +31.4% |
| Q3 2020 | $2,126,000 | -26.4% | 149,717 | -23.7% | 0.14% | -28.6% |
| Q2 2020 | $2,887,000 | +1171.8% | 196,240 | +256.2% | 0.20% | +988.9% |
| Q1 2020 | $227,000 | +11.3% | 55,100 | +29.6% | 0.02% | +38.5% |
| Q4 2019 | $204,000 | -6.4% | 42,500 | +18.1% | 0.01% | 0.0% |
| Q3 2019 | $218,000 | -6.8% | 36,000 | 0.0% | 0.01% | -7.1% |
| Q2 2019 | $234,000 | -8.2% | 36,000 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $255,000 | +15.4% | 36,000 | -20.7% | 0.01% | +16.7% |
| Q4 2018 | $221,000 | -14.3% | 45,400 | +29.3% | 0.01% | +9.1% |
| Q3 2018 | $258,000 | +10.7% | 35,121 | +18.8% | 0.01% | +120.0% |
| Q3 2015 | $233,000 | +65.2% | 29,569 | +117.4% | 0.01% | +25.0% |
| Q2 2013 | $141,000 | – | 13,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 3,500,000 | $25,725,000 | 3.13% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,830,399 | $28,153,000 | 1.28% |
| Mesirow Financial Investment Management, Inc. | 33,001 | $243,000 | 1.25% |
| Bellevue Group AG | 1,339,502 | $9,845,000 | 0.62% |
| NEEDHAM INVESTMENT MANAGEMENT LLC | 260,000 | $1,912,000 | 0.58% |
| Lyon Street Capital, LLC | 109,850 | $807,000 | 0.50% |
| Private Wealth Partners, LLC | 300,000 | $2,205,000 | 0.34% |
| Penn Capital Management Company, LLC | 455,064 | $3,345,000 | 0.25% |
| HighTower Advisors, LLC | 2,337,132 | $17,179,000 | 0.12% |
| Schonfeld Strategic Advisors LLC | 376,000 | $2,763,000 | 0.12% |